Mirum Pharmaceuticals (MIRM) Q2 2026 earnings review
Commercial Execution Shines, But Pipeline Hits a Regulatory Speedbump
Mirum delivered a stellar commercial quarter with total revenue surging 38% YoY to $176.2M, prompting management to raise FY26 guidance. LIVMARLI remains an absolute powerhouse, growing 46% as adult PFIC adoption accelerates. However, the commercial celebration is muted by a significant regulatory setback: the FDA is pushing back on the volixibat PSC filing, recommending a new Phase 3 trial instead of accepting the Phase 2b VISTAS data. Meanwhile, aggressive R&D spending and acquisition costs have ballooned the net loss to $67.2M, underscoring that while Mirum can sell approved drugs effectively, its transition into a multi-asset pipeline powerhouse will be expensive and delayed.
🐂 Bull Case
LIVMARLI growth is accelerating, proving that the strategy to target older adolescent and adult PFIC patients is highly successful. This asset alone is rapidly approaching a $500M annual run rate.
The NDA for zilurgisertib in FOP has a PDUFA date of September 26, 2026. If approved, Mirum will immediately launch a highly strategic, high-value asset to complement its existing rare genetics infrastructure.
🐻 Bear Case
The FDA's recommendation for a Phase 3 study in PSC reverses management's prior timeline. Pushing the potential NDA submission from H2 2026 to H1 2027 delays a critical catalyst and introduces new clinical execution risks.
Total operating expenses skyrocketed to $218.8M (up 65% YoY). Heavy R&D investments in brelovitug and zilurgisertib mean Mirum will burn cash for several more years before seeing GAAP profitability.
⚖️ Verdict: ⚪
Neutral. The commercial execution on LIVMARLI is flawless and supports the guidance raise, but the FDA's pushback on volixibat is a material negative that disrupts the near-term pipeline narrative. Investors are trading near-term commercial strength against long-term pipeline execution risk.
Key Themes
LIVMARLI's Unstoppable Momentum
Accelerating. LIVMARLI revenues surged 46% YoY to $128.7M. The primary growth engine is the successful penetration of the adult Progressive Familial Intrahepatic Cholestasis (PFIC) market. Management's strategic pivot to expand commercial focus from pediatrics to adult GI and liver specialists is yielding immediate, highly accretive returns.
Volixibat Regulatory Reality Check
Reversing. Despite touting a Breakthrough Therapy Designation and claiming the Phase 2b VISTAS study met its primary endpoint, the FDA has recommended a Phase 3 study for volixibat in PSC. Management is attempting to spin this positively by pointing to the drug's efficacy, but this specific regulatory pushback directly contradicts the previous narrative of an expedited H2 2026 filing. The NDA target is now delayed to H1 2027, assuming they can negotiate a path forward without a lengthy new trial.
Zilurgisertib Launch Readiness (Innovation)
Stable. Mirum is weeks away from a potential FDA approval for zilurgisertib, an oral ALK2 inhibitor for Fibrodysplasia Ossificans Progressiva (FOP). This represents a major product innovation and a strategic expansion of Mirum's rare genetic disease footprint. By inhibiting the ALK2 receptor to prevent heterotopic ossification (bone forming in soft tissues), Mirum is positioning an oral alternative against existing injectables in a highly concentrated patient population.
The Profitability Mirage
Decelerating. Revenue growth is fantastic, but operating expenses are growing faster. Q2 R&D expenses doubled YoY to $90.5M, driven by $28.8M allocated to brelovitug development. Combined with a non-recurring $16.4M IPR&D charge for the zilurgisertib license, total OpEx hit $218.8M. Mirum's transition into a multi-franchise company requires immense capital, effectively pushing GAAP profitability out to 2028.
Lack of Public Zilurgisertib Data Creates Blind Spots
Stable. Despite a PDUFA date scheduled for September 26, 2026, Mirum still has not released public data from the pivotal PROGRESS study. During the 26Q1 call, analysts repeatedly flagged this lack of transparency as a concern. Management claims they are fully confident based on their private due diligence of the data room, but asking investors to price in a successful commercial launch without seeing the underlying clinical data is a significant leap of faith.
Bile Acid Medicines Provide Crucial Cash Flow
Stable. The bile acid portfolio (CHOLBAM and CTEXLI) continues to act as a reliable cash cow, delivering $47.5M in Q2 (up 20% YoY). While not the primary growth engine, this steady execution provides essential non-dilutive capital to help offset the massive R&D spending required by the newer pipeline assets.
Other KPIs
Mirum significantly restructured its balance sheet this quarter. The company issued $690.0M in 0.00% convertible senior notes due 2032 and used a portion to settle $237.2M of older 4.00% notes. This maneuver eliminated interest expense on the new debt, pushed maturity out by three years, and padded the balance sheet to fund the heavy R&D cycle ahead.
Cost of sales was $23.2 million (excluding intangible amortization and SBC) on $176.2 million of revenue. This confirms that Mirum's commercial portfolio maintains elite, near-90% gross margins, typical for rare disease therapeutics. The core issue impacting the bottom line is strictly R&D and SG&A bloat, not unit economics.
Guidance
Accelerating. Management raised the full-year guidance from the previously stated $660-$680M. Using the midpoint ($690M), this implies a massive ~36% YoY growth over FY25's roughly $505M base. This reflects extreme confidence in the continued penetration of LIVMARLI in adult PFIC and international markets.
Key Questions
Volixibat FDA Negotiations
You mentioned holding further discussions with the FDA before a potential H1 2027 NDA submission for volixibat in PSC. If the FDA firmly demands a Phase 3 trial, how long will that delay the program, and what does the revised capital allocation look like for that asset?
Zilurgisertib Transparency
With the zilurgisertib PDUFA date just weeks away, the lack of public PROGRESS study data remains a glaring omission. Will full pivotal data be presented prior to the FDA decision, or will investors be forced to evaluate the launch blindly?
Brelovitug R&D Run Rate
R&D expense included $28.8M specifically for brelovitug this quarter. With the AZURE-1 and AZURE-4 Phase 3 readouts expected in Q3 and Q4, should we expect this specific R&D line item to plateau, or will commercial prep drive costs even higher into early 2027?